ASCO 2020：11项中国研究入选口头简报，17项Poster简报

曾受全球新冠疫情制约，原定于5年初29日~6年初2日在明尼阿波利斯举行的美国临床学会（ASCO）大会今年将首次以线或上型式举办，这是现在最大规模的线或上晚会。今天，全体会议的参考资料题目发布，共103个sessions，之中国共有11项学术研究被选为口头报告，17项被选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

苯甲酸替尼或拉帕替尼加卡培他丰可用HER2+结核乳腺胰脏（PHOEBE）：一项III期随机次测试。

第二场：结核乳腺胰脏

所作：之北京协和医学院所医院徐兵河讲师、马飞讲师，上海交通大学附属所医院胡夕春讲师等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可移植手术三阴性乳腺胰脏标准放射治疗后卡培他丰保持节拍抗生素的III期次测试（SYSUCC-001）。

第二场：乳腺胰脏—均匀分布/区域/辅助放射治疗

所作：之上海交通大学防治该之中心王树森讲师等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核脑的变异特征来预测循环系统之中循环DNA测定的概率: 新用以压制来由对手

第二场：新用以解决来由问题

所作：李美芹 李昔等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为更早大肠线或粒体胰脏的一线或放射治疗：一项对外开放首页、随机、多该之中心II/III期次测试。

第二场：上皮线或粒体胰脏—肠胃食管、胰脏和大肠胆

所作：重庆大学特罗斯季亚涅齐所医院毕锋讲师、人民解放军南昌所医院秦叔逵讲师等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中国更早大肠胰脏病人阿帕替尼二线或放射治疗：一项随机、低剂量对照、双盲III期学术研究

第二场：上皮线或粒体胰脏—肠胃食管、胰脏和大肠胆

所作：人民解放军南昌所医院秦叔逵讲师、重庆大学特罗斯季亚涅齐所医院李秋讲师等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早入院性卵巢胰脏二次线或粒体减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

研讨：外科胰脏症

所作：上海交通大学附属之松山所医院臧荣余讲师等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性阴囊输卵管后辅助放射治疗之中的序贯放抗生素对比单独前列腺癌或同步放抗生素（STARS学术研究）：一项随机、对照、对外开放首页的III期次测试。

全体会议：外科胰脏症

所作：之上海交通大学防治该之中心黄鹤讲师、刘继红讲师等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比抗生素可用可切除的EGFR基因的N1-N2期NSCLC-随机III期临床次测试的最终上都生存深入研究。

研讨：肺胰脏—非小线或粒体均匀分布-区域/小线或粒体/其他胸部

所作：广东省人民所医院吴一龙讲师等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因寡转回非小线或粒体肺胰脏病人一线或酪氨酸激酶抑制剂合组或不合组积极前线或均匀分布前列腺癌：III期对外开放首页临床随机次测试（SINDAS）的之后半期结果（NCT02893332）。

研讨：肺胰脏-非小线或粒体转回

所作：四川省人民所医院曾铭讲师等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4基因工程合组阿昔替尼可用结核黏膜黑色素瘤病人的Ib期学术研究的总生存期和生物标志物深入研究。

研讨：黑色素瘤/皮肤胰脏

所作：北京大学所医院郭军、盛锡楠讲师等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠性和结果：通用CAR-T线或粒体首次人体次测试放射治疗入院/难治性T线或粒体急性淋巴线或粒体肺炎（r/r T-ALL）的可靠性和。全体会议：共同开发之中的放射治疗新技术-免疫放射治疗。所作：斌欣等参考资料：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在更早食管楔形线或粒体胰脏病人之中的应用：一项随机的对外开放首页II期次测试（ORIENT-2）。全体会议：上皮线或粒体胰脏-肠胃食管胰脏、胰脏胰脏和大肠胆道胰脏所作：徐建明讲师等参考资料：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D甲基化CAR-T线或粒体对髓母线或粒体瘤的扫除性放射治疗全体会议：之大脑皮层所作：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东参考资料：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复缺陷病人之中的应用全体会议：共同开发之中的放射治疗学-免疫放射治疗所作：沈琳讲师等参考资料：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨髓CD7-CART放射治疗入院/难治性ACUTE淋巴线或粒体肺炎/霍奇金的首开人体临床次测试全体会议: 共同开发性放射治疗学-免疫放射治疗所作简介：张明志，杨林等参考资料：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 利是替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组应可用更早实体瘤病人的Ib期学术研究全体会议：发展性放射治疗学---分子靶向类固醇和遗传学所作：龚继芳，沈琳讲师等参考资料：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组嘌呤和nedaplatin放射治疗入院性或结核食管楔形线或粒体胰脏（ESCC）病人的II期学术研究。全体会议：上皮线或粒体胰脏-肠胃食管、胰脏和大肠胆道胰脏的学术研究所作：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼参考资料：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：上皮线或粒体胰脏-肠胃食管胰脏、胰脏胰脏和大肠胆管胰脏的二线或放射治疗所作：宋艳等参考资料：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体马蹄形RNA权重可用初始前列腺时测定高等级胰脏的尿液外体马蹄形RNA权重：一项多该之中心的回顾性学术研究全体会议：泌尿生殖系统胰脏症；还有胰脏、睾丸胰脏和胰脏所作简介：Liaoyuan Li等参考资料：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布更早宫颈胰脏并作抗生素后的辅助抗生素全体会议: 外科胰脏症所作简介： 李珉珉等参考资料：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗甲状腺髓性胰脏的相关性：基于ALTER01031次测试的深入研究。会福州话：多毛所作：济南市所医院得意讲师参考资料：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和岁数对安洛替尼放射治疗后病人结尾的制约: ALTER01031的亚组深入研究全体会议：多毛所作：济南市所医院得意讲师参考资料：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预测I-IIIA期非小线或粒体肺胰脏（NSCLC）病人术后入院: GASTO1035和GASTO1018的结果全体会议：肺胰脏-非小线或粒体均匀分布-区域性/小线或粒体/小线或粒体/其他胸科胰脏症所作：Si-Yu Wang等参考资料：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线或粒体肺胰脏（NSCLC）之中EGFR酪氨酸激酶抑制剂的新型耐药机制全体会议:肺胰脏-非小线或粒体结核肺胰脏所作简介：赵昕，金玲玲，满宇，欧妩媚，金兰，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧妩媚、金兰、薛武、杨绍、范敏参考资料：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试之中更早黑色素瘤总生存的替代终点全体会议：黑色素瘤/皮肤胰脏所作：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟参考资料：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗入院或结核原发性恶性骨病人的II期学术研究全体会议： 溃疡所作：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 下一步赞扬安罗替尼在更早溃疡病人多线或放射治疗之中的可靠性和。全体会议：溃疡所作：姚伟涛，来由强，张瑞，斌，杜新辉，田志浩，牛晓颖 姚伟涛、来由强、张瑞、王鑫、杜鑫辉、田志超、牛晓英参考资料：11526名片：414